BioNTech SE BNTX
NASDAQ BNTX
$103.76 +0.88 (+0.86%)
As of: Sep 4, 2026 · 3:59 PM EDT

BioNTech SE (BNTX) Non-Current Assets (2018 - 2026)

BioNTech SE (BNTX) posted Non-Current Assets of $6.8 billion for Q4 2025, up 5.56% sequentially from $6.4 billion in Q3 2025, and up 70.79% YoY from $4.0 billion in Q4 2024.

Analysis

BioNTech SE (BNTX) Non-Current Assets (2018 - 2026) Analysis & Trends

BioNTech SE has reported Non-Current Assets for 8 years, with the latest figure at $6.8 billion in Q4 2025.

  • Quarterly Non-Current Assets rose 70.79% year-over-year to $6.8 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $25.5 billion (up 51.46% YoY) and the FY2025 annual result came in at $6.6 billion, up 65.76% from the prior year.
  • Non-Current Assets climbed to $6.8 billion in Q4 2025 per BNTX's latest filing, from $6.4 billion in the prior quarter.
  • Over five years, Non-Current Assets peaked at $6.8 billion in Q4 2025 and troughed at $803.3 million in Q3 2021.
  • A 5-year average of $3.2 billion and a median of $3.5 billion in 2023 frame the typical range for Non-Current Assets.
  • The sharpest annual moves came in 2023 and 2024: Non-Current Assets surged 224.44% in 2023, then climbed 6.37% in 2024.
  • Over 5 years, Non-Current Assets stood at $867.7 million in 2021, then jumped by 59.57% to $1.4 billion in 2022, then surged by 170.35% to $3.7 billion in 2023, then climbed by 6.37% to $4.0 billion in 2024, then soared by 70.79% to $6.8 billion in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods registered $6.8 billion, $6.4 billion, and $6.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 14.88 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 23.28 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 1.96 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 5.15 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 294.93 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.96 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 938.60 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 18.06 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 468.65 Mn
10 BioNTech SE 25.06 Bn 11.41 Bn 10.00 Mn 5.86 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 5.86 Bn
Mar 31, 2026 6.49 Bn
Dec 31, 2025 6.80 Bn
Sep 30, 2025 6.44 Bn
Jun 30, 2025 6.46 Bn
Mar 31, 2025 5.85 Bn
Dec 31, 2024 3.98 Bn
Sep 30, 2024 4.30 Bn
Jun 30, 2024 4.26 Bn
Mar 31, 2024 4.33 Bn
Dec 31, 2023 3.74 Bn
Sep 30, 2023 3.76 Bn
Jun 30, 2023 3.28 Bn
Mar 31, 2023 2.14 Bn
Dec 31, 2022 1.38 Bn
Sep 30, 2022 1.40 Bn
Jun 30, 2022 1.01 Bn
Mar 31, 2022 935.47 Mn
Dec 31, 2021 867.70 Mn
Sep 30, 2021 803.33 Mn